Close

Insulet (PODD) Sales Momentum Appears Sustainable - Leerink; PT to $50

Go back to Insulet (PODD) Sales Momentum Appears Sustainable - Leerink; PT to $50

Insulet Reports Third Quarter 2016 Financial Results

November 3, 2016 4:01 PM EDT

Third Quarter Revenue of $94.9 Million, up 33% Year-Over-Year, Exceeds Expectations

Gross Margin Improves to 58.6%

Company Raises Full Year 2016 Revenue Guidance to a Range of $362 to $365 million, from $345 to $355 million; Approximately 38% Year-Over-Year Growth at Mid-Point

BILLERICA, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin... More